CLSD: the cashflow

MyFinsight

For the quarter ending 2025-09-30, CLSD had -$2,575K decrease in cash & cash equivalents over the period. -$5,480K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-5,972	-12,718
Non-cash interest expense on liability related to the sales of future royalties, net of issuance costs accretion	2,570	5,435
Depreciation	84	169
Share-based compensation expense	746	1,415
Change in fair value of warrant liabilities	-3,573	-1,927
Issuance costs allocated to warrant liabilities	0	0
Amortization and accretion of available-for-sale investments, net	0	0
Prepaid expenses and other current assets	-956	1,155
Other assets and liabilities	11	25
Accounts payable and accrued liabilities (includes 223 to a related party for the nine months ended september 30, 2024)	-280	-1,753
Deferred revenue	0	0
Net cash used in operating activities	-5,480	-10,559
Acquisition of property and equipment	0	9
Purchase of short-term investments	0	0
Maturity of short-term investments	0	-
Net cash used in investing activities	0	-9
Proceeds from issuance of common stock and warrants under registered direct offering, net of issuance costs	0	0
Proceeds from at-the-market sales agreement, net of issuance costs	0	1,411
Proceeds from royalty purchase and sale agreement, net of issuance cost	2,895	-
Payments on royalty purchase and sale agreement	0	1,500
Proceeds from exercise of stock options	0	0
Proceeds from shares issued under employee stock purchase plan	10	13
Net cash provided by financing activities	2,905	-76
Net decrease in cash and cash equivalents	-2,575	-10,644
Cash and cash equivalents at beginning of period	20,020	-
Cash and cash equivalents at end of period	6,801	-

Unit: Thousand (K) dollars